Inhibitor Therapeutics, Inc. announced on January 13, 2022 executed a letter agreement with Mayne Pharma to amend the Loan Agreement and the Facility (the “ Loan Amendment”). Under the terms of the Loan Amendment: amount of the facility was increased by $50,000 to $281,000, the maturity date of the Facility was extended to December 31, 2022 (the “ Maturity Date”), such $50,000 increase will be available for draw down from February 1, 2022 until March 31, 2022 in no less than $25,000 increments, following March 31, 2022, the outstanding amount under the Facility plus interest thereon will be amortized over equal monthly payments through the Maturity Date and the parties acknowledged that the full $231,000 under the original Facility had been drawn down by the Company.